Results 241 to 250 of about 617,584 (375)

The impact of treatment for muscle‐invasive bladder cancer on health‐related quality of life

open access: yesBJU International, EarlyView.
Objectives To evaluate the impact of treatment for localised muscle‐invasive bladder cancer (MIBC) during the first 2 years after diagnosis. Patients and Methods A prospective cohort study was conducted including patients diagnosed with non‐metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands. Health‐related quality of life (
Siberyn T. Nuijens   +9 more
wiley   +1 more source

A GLP‐1R/Y1 receptor/Y2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Emerging literature indicates that simultaneously targeting glucagon‐like peptide‐1 receptors (GLP‐1Rs) and neuropeptide Y receptors (Y1/Y2) may represent a new pharmacotherapeutic approach to treating opioid use disorder (OUD).
Antonia Caffrey   +5 more
wiley   +1 more source

Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology [PDF]

open access: hybrid, 2018
Uday C. Ghoshal   +28 more
openalex   +1 more source

CDK13‐Related Disorder: Novel Insights From A Series of 27 Cases and Recommendations for Clinical Management

open access: yesClinical Genetics, EarlyView.
This report described 27 novel subject with CDK13‐related disorders. Collecting the clinical and radiological data, we better define the phenotypic spectrum of this condition and we suggest a comprehensive clinical management. ABSTRACT In 2016, Sifrim and colleagues described the first group of patients carrying heterozygous pathogenic variants in ...
Gianluca Contrò   +57 more
wiley   +1 more source

Clinical and Neurodevelopmental Characteristics of Paralogous Gain‐of‐Function Variants at GRIA2 p.Gly792 and GRIA3 p.Gly803

open access: yesClinical Genetics, EarlyView.
Key features of paralogous GRIA2 and GRIA3 gain‐of‐function variants. ABSTRACT GRIA‐related disorders arise from disease‐causing variants in GRIA1, GRIA2, GRIA3, or GRIA4 that encode α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid (AMPA)‐type glutamate receptors (AMPARs).
Emilie Sjøstrøm   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy